Posted by Michael Wonder on 03 Dec 2020
Fate of 250,000 diabetics in PHARMAC’s hands
3 December 2020 - This week, a small group of bureaucrats and health professionals will meet to agree on the quality of life of at least a million people; the 250,000 New Zealanders with diabetes and their families.
The Board of New Zealand’s medical agency, PHARMAC, will consider whether to fund two new medicines which will dramatically change their lives; empagliflozin and dulaglutide.
